Neuberg becomes the first lab chain of Indian origin to start direct operations in the USA with CLIA certified lab operations.
Neuberg Diagnostics, a global laboratory testing group, announced the start of its clinical laboratory operations in North Carolina in the United States of America (USA). The laboratory in North Carolina, known as NCGM, Inc. (Neuberg Centre for Genomic Medicine), will focus on genomic and molecular testing based on new generation sequencing techniques. It also runs an extensive network of labs in India, South Africa, and the UAE as well.
NCGM has introduced COVID-19 molecular testing to detect active SARS CoV-2 virus infections that is of immediate public health priority in North America, along with genome scale testing, such as Exome Sequencing, which is applicable across a variety of Rare Genetic Disease Testing (Inherited Diseases) from Newborn Screening to Oncology to Pediatric Care Setting.
Dr. Sandip Shah, Executive Director Neuberg Diagnostics said “NCGM, USA Sequencing services will be supported by in-house bioinformatics team and cutting-edge technologies which has been developed inhouse, and along with reputed partners. It will also support genetic research by leveraging our own extensive infrastructure in India, South Africa, and UAE.”
Dr. Andy Bhattacharjee, CEO, NCGM, USA said “The setup has comprehensive Genomic testing facility allowing large-scale clinical and research projects. With capacity to conduct more than 400 variety of tests, the center will conduct large-scale clinical diagnostics and genomics projects with greater sample volumes at an unprecedented depth and coverage of the genome. Currently we are offering Covid RT-PCR Testing Services at our NC Lab with home sample collection facilities in association with FexEx to help fight the pandemic in USA too. “